Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage

Current Opinion in HIV and AIDS

Volumn 10, Issue 1, 2015, Pages 35-42

  Rajasuriar, Reena ^a,b   Wright, Edwina ^b,c   Lewin, Sharon R ^b,c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b ALFRED HOSPITAL   (Australia)

^c BURNET INSTITUTE   (Australia)

Author keywords

CD4:CD8 ratio; Early antiretroviral therapy; Immune activation; Serious non AIDS events; Viral persistence

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

BLOOD CLOTTING; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; END ORGAN DAMAGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; ORGAN INJURY; PERSISTENT VIRUS INFECTION; REVIEW; T LYMPHOCYTE ACTIVATION; CHEMICALLY INDUCED; CHRONIC DISEASE; COMPLICATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; VIREMIA;

ANTI-RETROVIRAL AGENTS; CD4-CD8 RATIO; CHRONIC DISEASE; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; VIREMIA;

EID: 84918525719     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000118     Document Type: Review

References (50)

1. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviraltreatment. J Infect Dis 2014; 210:1248-1259.
2. McComsey GA, Kitch D, Sax PE, et al. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr 2014; 65:167-174.
3. Serrano-Villar S, Perez-Elias MJ, Dronda F, et al. Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One 2014; 9:e85798.
4. Hsu DC, Sereti I, Ananworanich J. Serious Non-AIDS events: immunopathogenesis and interventional strategies. AIDS Res Ther 2013; 10:29.
5. Lichtfuss GF, Hoy J, Rajasuriar R, et al. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med 2011; 5:171-186.
6. + T cells. J Infect Dis 2009; 200:1212-1215.
7. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
8. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
9. Ostrowski SR, Katzenstein TL, Pedersen BK, et al. Residual viraemia in HIV-1-infected patients with plasma viral load
10. + T cells. J Infect Dis 2013; 208:50-56.
11. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-1236.
12. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208:1202-1211.
13. Buzon MJ, Martin-Gayo E, Pereyra F, et al. Long-term antiretroviral treatment initiated in primary HIV-1 infection affects the size, composition and decay kinetics of the reservoir of HIV-1 infected CD4 T cells. J Virol 2014; 88:10056-10065.
14. Vinikoor MJ, Cope A, Gay CL, et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr 2013; 62:505-508.
15. Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013; 68:1169-1178.
16. Chevalier MF, Petitjean G, Dunyach-Remy C, et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog 2013; 9:e1003453.
17. + T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10:e1004078.
18. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7:e33948.
19. Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of 3-versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr 2014; 66:140-147.
20. Ananworanich J, Vandergeeten C, Chomchey N et al. Early ART intervention restricts the seeding of the HIV reservoir in long-lived central memory CD4 T Cells. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 3-6 March 2013. Abstract 47.
21. Jenabian M-A, Vyboh K, Kema I et al. A longitudinal assessment of host immunosuppressive responses in primary and chronic HIV infection. 20th International AIDS Conference, Melbourne, 20-25 July 2014. Abstract MOPE018.
22. Schuetz A, Phuang-Ngern Y, Rerknimitr R, et al. Early ART initiation prevents disruption of the mucosal barrier and subsequent T-cell activation. CROI abstract 77]. In special issue: abstracts from the 2014 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med 2014; 22 (e-1-1):38.
23. Deleage C, Schuetz D, Morcock D et al. Early treatment during HIV-1 acute infection attenuates GI damage, inflammation and immune activation but does not prevent CD4 T-cell depletion in the lamina propria. 20th International AIDS Conference, Melbourne, 20-25 July 2014. Abstract WEAA0105.
24. Hazenberg MD, Otto SA, van Benthem BHB, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
25. Wikby A, Ferguson F, Forsey R, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005; 60:556-565.
26. Ferrando-Martinez S, Romero-Sanchez MC, Solana R, et al. Thymic function failure and C-reactive protein levels are independent predictors of all-cause mortality in healthy elderly humans. Age (Dordr) 2013; 35:251-259.
27. Sainz T, Serrano-Villar S, Diaz L, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS 2013; 27:1513-1516.
28. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368:218-230.
29. Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active anti-retroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 83:11407-11411.
30. Macal M, Sankaran S, Chun TW, et al. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol 2008; 1:475-488.
31. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011; 203:1637-1646.
32. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
33. Chun TW, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-138.
34. Murray JM, Zaunders JJ, McBride KL, et al. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy. J Virol 2014; 88:3516-3526.
35. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013; 254:326-342.
36. Cameron PU, Saleh S, Sallmann G, et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A 2010; 107:16934-16939.
37. Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 2014; 111:2307-2312.
38. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
39. Maldarelli F, Wu X, Su L, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014; 345:179-183.
40. Khoury G, Anderson J, Fromentin R, et al. CXCR3 and CCR5 expression are associated with 2LTR circles in patients on antiretroviral therapy. [CROI abstract 414]. In special issue: abstracts from the 2014 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med 2014; 22 (e-1): 196.
41. Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014; 512:74-77.
42. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
43. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 2014; 28:1015-1020.
44. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-1835.
45. Smith CJ, Ryom L, Weber R, et al., D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241-248.
46. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al., HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14:281-290.
47. 3. AIDS Res Hum Retroviruses 2013; 29:1161-1167.
48. Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroima-ging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 2013; 207:1703-1712.
49. Yilmaz A, Yiannoutsos CT, Fuchs D, et al. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 2013; 10:62.
50. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis 2013; 57:756-764.